Angion Biomedica Corp.

55 articles about Angion Biomedica Corp.

• 

  Clinical Catch-Up: October 25-29

  11/1/2021

  Yet another busy week for clinical trial news. Here’s a look.

• Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function

  10/27/2021

  Vifor Pharma and Angion Biomedica Corp. announced that the phase-III trial of Angion’s ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint in the population of deceased donor kidney transplant patients who were at risk for developing DGF.

• 

  Angion and Vifor Disappointed After Phase III Kidney Transplant Study Fails

  10/27/2021

  ​The clinical study on ANG-3777 demonstrated a modest but not clinically significant difference in the placebo group's estimated glomerular filtration rate. 

• Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk for Delayed Graft FunctionAngion to host a conference call at 4:30 p.m. EDT

  10/26/2021

  Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion’s ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing delayed graft function (DGF).

• Angion to Present Multiple Posters at Kidney Week 2021

  10/18/2021

  Angion Biomedica Corp today announced it will be presenting four posters at the American Society of Nephrology’s Kidney Week 2021 virtual meeting to be held November 4-7, 2021.

• Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis

  9/8/2021

  Angion Biomedica Corp. announced it is scheduled to host a virtual research and development day focused on its product candidate ANG-3070, a novel, highly selective, and orally-bioavailable small molecule tyrosine kinase receptor inhibitor in clinical development for the treatment of fibrotic diseases, including those in the kidney and lung, at 10:00am EDT on Monday, September 20th.

• Angion to Participate in Upcoming September 2021 Investment Conferences

  9/2/2021

  Angion Biomedica Corp announced its management team will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference and participate in a fireside chat with Oppenheimer Senior Biotech Analyst Justin Kim at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

• Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results

  8/12/2021

  Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provided a corporate update and reported financial results for the quarter ended June 30, 2021.

• 

  Clinical Catch-Up: August 2-6

  8/9/2021

  It was a busy week for clinical trial announcements. Take a look.

• Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021

  8/3/2021

  Angion Biomedica Corp announced positive results from its Phase 1 study in healthy volunteers for ANG-3070, a novel oral tyrosine kinase receptor inhibitor being developed for the treatment of fibrotic diseases.

• 

  Clinical Catch-Up: June 28-July 2

  7/6/2021

  It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.

• Angion Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia

  6/29/2021

  Angion Biomedica Corp. (NASDAQ:ANGN), today announced that its exploratory Phase 2 ALI-201 trial of ANG-3777 in patients with severe COVID-19 related pneumonia at high risk for acute respiratory distress syndrome (ARDS) did not meet the primary or secondary efficacy endpoints.

• Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results

  5/17/2021

  Angion Biomedica Corp, a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, provided a corporate update and reported financial results for the quarter ended March 31, 2021.

• Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury

  4/29/2021

  Vifor Pharma and Angion Biomedica Corp., announced completion of enrollment for Angion’s AKI-002-15 study, a phase-II trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury.

• Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney InjuryTopline data expected in the second half of 2021

  4/29/2021

  Angion Biomedica Corp and Vifor Pharma announced completion of enrollment for Angion’s AKI-002-15 study, a Phase 2 trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury.

• Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

  3/30/2021

  Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2020.

• Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated PneumoniaTopline data expected in the first half of 2021

  3/25/2021

  Angion Biomedica Corp. announced completion of enrollment for its ALI-201 study, a Phase 2 trial conducted in Brazil of ANG-3777 for the reduction of severity and progression of acute lung injury in patients with COVID-19 associated pneumonia who are at high risk of progressing to acute respiratory distress syndrome, or ARDS.

• Angion to Participate in Upcoming March 2021 Investment Conferences

  2/24/2021

  Angion Biomedica Corp., a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, announced its management team will present at the H.C. Wainwright Global Life Sciences Conference and the Oppenheimer 31st Annual Healthcare Conference.

• Angion Biomedica Corp. Announces Closing of $117 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

  2/9/2021

  Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the closing of $117 million in gross proceeds from its previously announced initial public offering and concurrent private placement.

• Angion Biomedica Corp. Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement

  2/5/2021

  Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the pricing of its initial public offering on February 4, 2021 of 5,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $80,000,000 million,